KORU Medical Systems, Inc. (KRMD)

KORU Medical Systems, Inc. (KRMD) stock has increased by 56.54% between October 15, 2024, and October 15, 2025. Key positive events include record Q1 2025 financial results with an 18% revenue increase and raised full-year guidance, record Q2 2025 financial results with 21% year-over-year revenue growth and raised 2025 revenue guidance, an agreement with ForCast Orthopedics for a novel antibiotic infusion therapy, and the announcement of the Q3 2025 financial results report date. Market sentiment has fluctuated, with some periods of coolness towards the company's revenues and earnings, leading to a share drop of 28% at one point.

Specific demand seasonality information for KORU Medical Systems, Inc.'s products and services is not explicitly available. Demand may be relatively stable throughout the year due to the use of their products for chronic illnesses.

KORU Medical Systems, Inc. (KRMD) is a medical technology company focused on developing, manufacturing, and commercializing subcutaneous infusion solutions within the Healthcare sector, specifically the Medical Instruments & Supplies industry. They provide solutions for patients with chronic illnesses like primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). Their main products include the FREEDOM60® and FreedomEdge® syringe drivers, HIgH-Flo™ subcutaneous safety needle sets, and precision flow rate tubing, which form the Freedom Integrated Infusion System. The company rebranded from Repro Med Systems, Inc. to KORU Medical Systems, Inc. in March 2022.

KORU Medical Systems, Inc. develops, manufactures, and commercializes its subcutaneous infusion solutions for the subcutaneous drug delivery market in the United States and internationally. The company has reported strong growth in both domestic and international markets.

KORU Medical Systems' brand reputation is generally positive, particularly among analysts, with a consensus "Moderate Buy" rating. The stock's performance has exceeded both the US Medical Equipment industry and the broader US Market over the past year. Strong financial results and raised revenue guidance in Q1 and Q2 2025 have further bolstered its reputation. There is no specific information available about events that have negatively affected KORU Medical Systems, Inc.'s reputation in the past year, beyond general market fluctuations impacting stock price.

KORU Medical Systems, Inc. (KRMD) has a diverse ownership structure. Institutional shareholders hold 41.94% of the stock, insiders own 46.25%, and retail investors hold 11.81%. Major institutional owners include First Light Asset Management, LLC, Topline Capital Management, LLC, Vanguard Group Inc, BlackRock, Inc., Geode Capital Management, Llc, Meros Investment Management, LP, and Archon Capital Management LLC. Key individual insider owners include Joseph M. Manko Jr., Kathy Frommer, Paul Mark Baker, Linda M. Tharby (CEO), and Remo Spagnoli.